| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | LAG525 |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.[1]
Ieramilimab's first clinical trial is a Phase I in patients with various solid tumors, in combination with spartalizumab (PDR001), an anti-PD-1 monoclonal antibody has been completed.[2] Recruiting for a phase 2 study in combination with spartalizumab for the treatment of metastatic melanoma is underway.[3]
References
- ↑ "Meet Novartis Management presentation, 17/18 June 2015" (PDF). Novartis. Retrieved 9 July 2015.
- ↑ Clinical trial number NCT02460224 for "Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies." at ClinicalTrials.gov
- ↑ Clinical trial number NCT03484923 for "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PLATforM)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.